RPE65 Gene Therapy
1 drugs1
Approved Drugs
1
Companies
0
Indications
0
Therapeutic Areas
Top RPE65 Drugs
RPE65 Drug Modality Landscape
Modalities
Gene therapy
1
100%
Routes of Administration
💧 Other
1
100%
💡
Only one approved drug targets RPE65, using gene therapy modality.
Biologics only
RPE65 Clinical Trials 2 trials
2
Total Trials
2
Active
0
Completed
N/A
Completion Rate
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
Spark Therapeutics, Inc. 2
By Modality
Gene therapy 2
Top Conditions
Leber Congenital Amauro... 2
Inherited Retinal Dystr... 1
Top Drugs
Luxturna 2
Source: ClinicalTrials.gov · Completion rate = completed ÷ (completed + terminated + withdrawn)
RPE65 Drug Approval Timeline (2017 - 2017)
2017
Luxturna (Voretigene Neparvovec)
LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associa...
Modalities: Gene therapy | First of modality
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Success rates by condition
Unlock Full Intelligence
Full summary • All drugs • Genetic evidence • Trials • Timeline